Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7519328 | 0.82 | TSHR (1.00) | TSHRCYP1A2CYP2C9CYP2C19KIF11 | |
| SCHEMBL17171671 | 0.77 | TSHR (0.77) | TSHRCYP1A2CYP2C9CYP2C19KIF11 | |
| SCHEMBL7270519 | 0.72 | TSHR (0.68) | TSHRCYP1A2CYP2C9CYP2C19KIF11 | |
| Hydrochloric Acid SCHEMBL9873251 | 0.70 | TSHR (0.65) | TSHRCYP1A2CYP2C9CYP2C19KIF11 | |
| SCHEMBL16127134 | 0.69 | TSHR (0.37) | TSHR | |
| SCHEMBL12424582 | 0.69 | TSHR (0.62) | TSHRCYP1A2CYP2C9CYP2C19KIF11 | |
| SCHEMBL14418578 | 0.69 | TSHR (0.62) | TSHRCYP1A2CYP2C9CYP2C19KIF11 | |
| SCHEMBL8167005 | 0.67 | TSHR (0.59) | TSHRCYP1A2CYP2C9CYP2C19KIF11 | |
| SCHEMBL8316390 | 0.67 | TSHR (0.59) | TSHRCYP1A2CYP2C9CYP2C19KIF11 | |
| SCHEMBL8316383 | 0.67 | TSHR (0.59) | TSHRCYP1A2CYP2C9CYP2C19KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | Guris, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-10844056-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200062754-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2020-02-27 | — | — | US | disclosed |
| US-10428068-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190010152-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2019-01-10 | — | — | US | disclosed |
| US-10035797-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170267674-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-9630965-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160058742-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2016-03-03 | — | — | US | disclosed |
| US-9040556-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140221343-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8586605-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2069324-B1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8324240-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2012-09-20 | — | — | US | disclosed |
| EP-2069324-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | Curis, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008115719-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010152-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | TSHR 3700/4885CYP1A2 3736/4885CYP2C9 4323/4885 |
| US-10428068-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | TSHR 3700/4885CYP1A2 3736/4885CYP2C9 4323/4885 |
| US-20170267674-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | TSHR 3700/4885CYP1A2 3736/4885CYP2C9 4323/4885 |
| US-20160058742-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | TSHR 3700/4885CYP1A2 3736/4885CYP2C9 4323/4885 |
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | TSHR 3700/4885CYP1A2 3736/4885CYP2C9 4323/4885 |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | TSHR 3700/4885CYP1A2 3736/4885CYP2C9 4323/4885 |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | TSHR 3700/4885CYP1A2 3736/4885CYP2C9 4323/4885 |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | TSHR 3700/4885CYP1A2 3736/4885CYP2C9 4323/4885 |
| US-20200062754-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | TSHR 3700/4885CYP1A2 3736/4885CYP2C9 4323/4885 |
| US-20140221343-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | TSHR 3700/4885CYP1A2 3736/4885CYP2C9 4323/4885 |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | TSHR 3700/4885CYP1A2 3736/4885CYP2C9 4323/4885 |
| US-10844056-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | TSHR 3700/4885CYP1A2 3736/4885CYP2C9 4323/4885 |
| US-10035797-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | TSHR 3700/4885CYP1A2 3736/4885CYP2C9 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.